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I ABSTRACT 
With the recent advent of combinatorial chemistry and high throughput screening of 
potentially therapeutic agents, the number of poorly soluble drug candidate has risen 
sharply and the formulation of poorly soluble compounds for oral delivery now presents 
one of the most frequent and greatest challenge to formulation scientists in the 
phamiaceutical industry. There are certain drugs for which solubility has presented a 
challenge to the development of a suitable formulation for oral administration. And one 
of these drugs is carbamazepine. In the literature, solid dispersions have shown 
tremendous potential for improving drug solubility and dissolution. 
In this study the main objective was to enhance the solubility of carbamazepine using 
selected water-soluble polymers and a solid dispersion technique. The solid dispersions 
were prepared by fusion method, using water-soluble polymers as carriers, namely 
Solutol HS, Vitamin E TPGS, Poloxamer 188 and Lipocol C 10 at a fixed ratio of 9: 1 
(drug:carrier) was used. Physical and recrystallized mixtures of the same ratios were also 
prepared for comparison purpose. Solubility studies were carried out in distilled water for 
a period of 48 hours with sample analysis at nine time intervals. The drug concentration 
was measured using a spectrophotometer at 285 nm. Differential Scanning Calorimetry 
(DSC) and powder X-ray diffraction (XRD) were used to characterize all the 
preparations. Optimized ratios of the solid dispersions were determined and used for 
dissolution studies by comparing D 10 (dissolution rate at 10 min) values for each ratio. A 
USP dissolution apparatus II using 900 ml of simulated gastric fluid at 50 rpm was used. 
( Microfluidization studies were also conducted to determine the effects of shear stress on 
the solubility of solid dispersions. 
The solubility and dissolution rate of carbamazepine improved considerably with solid 
dispersions for all the selected polymers as compared to physical mixtures and 
recrystallized mixtures. Statistical analysis showed that both polymer and process had a 
significant effect on the solubility of the carbamazepine. Microfluidization studies 
initially showed a spike in drug solubility then a rapid drop back to equilibrium 
solubility. There was no significant effect of shear stress on the equilibrium solubility of 
solid dispersions of carbamazepine. Solid dispersions prepared with Vitamin E TPGS 
show maximum solubility as compared to solid dispersion prepared with other water-
soluble polymers. It has also been seen that dissolution rate is enhanced to greater extent 
for solid dispersion prepared with Vitamin E TPGS compared to solid dispersion 
prepared with other water soluble polymers. 
In general , solubility increase as well as dissolution rate enhancement was greater in solid 
dispersions than in physical mixtures and recrystallized mixture. 
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( PREFACE 
This document has been prepared in the format of a manuscript plan in accordance to 
section 11-3 of the graduate manual at the University of Rhode Island. This Thesis has 
been divided into three sections. 
Section I contains the introduction, the statement of the problem and a brief 
introduction to the objectives of this research. Section II forms the central part of this 
thesis and is composed of one manuscript written in the format prescribed by the 
scientific journal to which it has been or will be submitted for publication. This 
Section follows appendices that include the list of publications and experimental 
details useful for a clearer understanding of the results described in the preceding 
manuscripts . A general summary of conclusions and bibliography for the entire thesis 
follows this section. 
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SECTION 1 
1.1 Background: 
The advent of high throughput screening (HTS) for search of model drugs during the 
1989-1991-time period made it feasible to screen for in-vitro activity across hundreds 
of thousands of compounds (1). Combinatorial chemistry soon began and allowed 
automated synthesis of massive numbers of compounds for screening using new HTS 
screens. Since HTS is trying to maximize receptor site affinity and since hydrophobic 
molecules tend to provide better interaction at the receptor site, the resultant 
compounds are relatively high molecular weight and highly lipophilic. These kinds of 
molecules show poor solubility in water and in turn poor bioavailability. The 
enhancement of the solubility of poorly soluble drugs for better bioavailability poses 
one of the most challenging aspects of drug development (2). 
One of the drugs that pose challenges for better bioavailability due to poor water 
solubility is Carbamazepine. Carbamazepine is classified as an anticonvulsant. It has a 
chemical composition of C 15H 12N20 and molecular weight of 236.27. Its chemical 
name is 5H- Dibenz (b,f) azepine-5-carboxamide and its structural formula is as follows 
(3). It is a specific analgesic for trigeminal neuralgia. It is also indicated for the 
epilepsy, bipolar disorder and acute mania (4). 
Carbamazepine is a white to off-white powder, practically insoluble in water, soluble in 
alcohol and acetone. It is available as chewable tablets of 100 mg, 200 mg, as extended 
release tablets of 100 mg, 200 mg, 300 mg, 400 mg, and a suspension of 100 mg/5 ml 
(5). The melting point ofCarbamazepine is in the range of 190-193° C. 
N 
A 0 NH~ I . 
FIGURE 1. STRUCTURAL FORMULA OF CARBAMAZEPINE 
Carbamazepine is characterized by low and erratic absorption. Carbamazepine induces 
its own metabolism and that's why it has variable half-life. Autoinduction is completed 
after 3-5 weeks of fixed dosing regimen. Initially half-life values range from 26-65 
hours, decreasing to 12-17 hours after repeated doses. Carbamazepine is metabolized in 
liver. Cytochrome P450 3AA was identified as the major isoform responsible for the 
formation of Carbamazepine-10, 11-epoxide. After oral administration, 72% is 
eliminated in the urine and 28% in the feces. Carbamazepine has at least four 
polymorphic forms and a dihydrate (6) . 
2 
( 1.2 Methods to Improve Solubility of a Drug 
Together with permeability, the solubility behavior of a drug is a key determinant of its 
bioavailability. Consideration of the modified Noyes-Whitney equation (7) provides an 
indication as to how the dissolution rate of even poorly soluble compounds might be 
improved so that the limitations of oral availability can be minimized: 
de AD(Cs-C) 
dt h 
Where, dc/dt is the rate of dissolution, A is the surface area available for dissolution, D 
is the diffusion coefficient of the compound, Cs is the solubility of the compound in the 
dissolution medium, C is the concentration of the medium at time t and h is the 
thickness of the diffusion boundary layer adjacent to the surface of the dissolving 
compound. 
The main possibilities for improving dissolution according to this analysis are to 
increase the surface area available for dissolution by decreasing the particle size of the 
solid compounds, to decrease the boundary layer thickness, and last not but least, to 
improve the apparent solubility of the drug under physiologically relevant conditions. 
Of these possibilities, the most attractive option for increasing the release rate is the 
improvement of the solubility through fommlation approaches. Table 1 summarizes the 
various formulation and chemical approaches that may be used to improve the 
solubility or to increase the available surface area for dissolution. 
3 
TABLE 1: APPROACHES TO IMPROVE THE SOLUBILITY OR TO 
INCREASE THE AVAILABLE SURFACE AREA FOR DISSOLUTION (12) 
L Physical Modifications IL Chemical Modifications 
Particle size Soluble prodrugs 
Micronization Salts 
Nanosuspensions 
Modification of the crystal habit 
Polymorphs 
Pseudopolymorphs 
Complexation/ Solubilization 
Use of surfactant 
Use of acceptable cyclodextrins 
Drug dispersion in carriers 
Eutectic mixtures 
Solid dispersions (non-molecular) 
Solid solutions 
4 
( Of the physical approaches, the use of polymorphs (8), the amorphous form of the drug 
(9) and complexation ( 10, 11) has been widely reviewed. Decreasing the particle size of 
the compound by milling the drug powder theoretically results in an increase in the 
surface area for dissolution. However in those cases where the micronized powder 
agglomerates, is negating the advantages of the milling procedure. Presenting the 
molecular dispersion of a drug in a water soluble polymer, on the other hand, combines 
the benefits of a subsequent increase in the solubility by maximizing the surface area of 
the compound that comes in contact with the dissolution medium as the carrier 
dissolves. 
5 
1.3 Solid dispersions 
The term solid dispersion has been utilized to describe a family of dosage forms 
whereby the drug is dispensed in a biologically inert matrix, usually with a view to 
enhancing oral bioavailability. Sekiguchi and Obi introduced the concept of solid 
dispersion in 1961 (13). They proposed formation of a eutectic mixture of a poorly 
soluble drug with a physiologically inert, easily soluble carrier. The eutectic mixture 
was prepared by melting the physical mixture of the drug and the carrier, followed by 
rapid solidification procedure. Upon exposure to aqueous fluids, the active drug 
released into the fluids are fine, dispersed particles because of the fine dispersion of. the 
drug and rapid dissolution of the soluble matrix. 
The advantage of solid dispersion, compared with conventional capsule and tablet 
formulations , is shown schematically in Figure 2. (14) 
. .---------- ···· . 
L S-"dP ,, f : Drrnfn G.I. :, arge u111 a11.c a --·--- · ¥" Colloidal Particlest 
(U$Uafly 5-1"10 mfn:IWls) 1 .... -~~:!. __ .; Fin• Olly Globulr-!# 
(U!i1.t11lly <1 mlt;.rQll) 
Lower D'uf.>I~ /-Hfgher OJR>oluti-·11 Rt · 'ufJon~ R · 
'
1 
e ABSORPTTON ate 
INTO BODY SYSTEMS 
FIGURE 2. SCHEMATIC REPRESENTATION OF THE BIOAV AILABILITY 
L THA, TC£1 I~· TT 0 PO"~LY VATE so CB r: DR G n r SOLi 
DISPERSION COMPARED WITH CONVENTIONAL TABLET OR CAPSULE 
(14) 
6 
Chiou and Riegelman, ( 15) in their early classic review, defined these systems as " a 
dispersion of one or more active ingredients in an inert carrier or matrix at solid state 
prepared by melting (fusion), solvent or melting-solvent methods". The formulation 
prepared by any of these processes, classified as solid dispersions but simple 
mechanical mixes are not considered to be solid dispersions. 
Corrigan (16) suggested the definition of solid dispersion as being a ' product formed 
by converting a fluid drug-carrier combination to solid state'. In practice, these dosage 
forms have been traditionally regarded as being synonymous with systems whereby the 
in vitro release of the drug is enhanced compared to conventional dosage forms , with 
concomitant implications for in vivo release. Furthermore, the carrier used has, again 
traditionally, been a water-soluble or water miscible polymer such as polyethylene 
glycol (PEG) or polyvinylpyrolidone (PVP) or low molecular weight materials such as 
sugars. However, the proliferation of research in the area since the first solid 
dispersions were described has led to a broadening of these definitions to include water 
insoluble matrices such as Gelucires® and Eudragits® that may yield either slow or 
rapid release and absorption. The latest review publication by Serajuddin (1999) (14) 
gives details of some more recent approaches such as the use of surface active carriers 
and the use of melt extrusion of PVP dispersions as a means of manufacturing viable 
dosage forms using this technology. 
Solid solutions are comparable to liquid solutions, consisting of just one phase 
irrespective of the number of components, and are made up of a solid solute dissolved 
in a solid solvent. It is often called a mixed crystal because the two components 
crystallize together in a homogenous one-phase system (17). Solid solutions containing 
7 
I a poorly water soluble drug dissolved in a earner with relatively good aqueous 
solubility achieve a faster dissolution rate because the particle size of the drug in the 
solid solution is reduced to a minimum state, i.e. , its molecular size, and the dissolution 
rate is determined by the dissolution rate of the carrier (18). By judicious selection of a 
carrier, the dissolution rate of the drug can be increased by up to several orders of 
magnitude. 
In addition to the reduction of the crystalline size, the following factors may contribute 
to the faster dissolution rate of a drug dispersed in these systems (19), 
a) An increase in drug solubility may occur if the majority of its solid crystallites are 
extremely small (20). 
b) A solubilization effect by the earner may operate the microenvironment 
(diffusion layer) immediately surrounding the drug particle in early stages of 
dissolution since the carrier completely dissolves in a short time. This was 
demonstrated by the faster dissolution rate of acetaminophen from its physical 
mixtures with urea than that of the pure compound with comparable particle size (21 ). 
c) The absence of aggregation and agglomeration between fine crystallites of the 
pure hydrophobic drug may play a far more important role in increasing rates of 
dissolution and absorption than is presently recognized. Serious drawbacks of 
aggregation and agglomeration and lumping in the dissolution medium between pure 
drug particles are, however, rarely present in most solid dispersion systems because 
the individually dispersed particles are surrounded in a matrix of carrier particles. It 
be must emphasized that the aggregation and agglomeration of the solid dispersion 
powder may not significantly affect the dissolution of the drug, which can still 
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( disintegrate quickly due to more rapid dissolution of the soluble earner. This 
advantage of solid dispersion systems was demonstrated in vivo (22) for griseofulvin 
that was dispersed in polyethylene glycol 6000 (10% w/w) and compressed into a 
hard tablet. The dissolution rate of the dispersed drug was found to be 25 times that 
of the pure drug. 
d) Excellent wettability and dispersibility of a drug from those systems, prepared 
with a water-soluble matrix results in an increased dissolution rate for the drug in 
aqueous media. This is due to the fact that each single crystallite of the drug is very 
intimately encircled by the soluble matrix, which can readily dissolve and cause the 
water to contact and wet the drug particle. As a consequence, a fine homogenous 
suspension of a drug can be easily obtained with minimum stirring ( l 3). 
9 
1.4 Analytical methods used to characterize solid dispersions 
In order to differentiate between solid dispersions and solid solutions and physical 
mixtures of the drug in a carrier following methods are used to characterize. 
1) Solubility and dissolution testing 
2) Thermoanalytical methods: differential thermo analysis and hot stage microscopy 
3) X-ray diffraction 
4) Surface properties studies 
5) Spectroscopic methods such as FT-IR spectroscopy 
6) Microscopic methods including polarization microscopy and scanning electron 
microscopy. 
Among these, the most important methods are Thermoanalytical, X-ray diffraction and 
measurement of the release rate of the drug. It is difficult to differentiate precisely 
between molecularly dispersed and not molecularly dispersed systems. 
Since it is usually assumed that the dispersions in which no crystallinity can be detected 
are molecularly dispersed and the absence of crystallinity is used as criterion to 
differentiate between solid solutions and solid dispersions (12). 
1.4.1 Differential scanning calorimetry (DSC): 
Thermoanalytical methods include an examination of system properties as a function of 
temperature. Most thermodynamic events are accompanied by a loss of heat or require 
addition of heat from an external source in order to proceed. Each of these occurrences 
can be followed thermodynamically by noting either change of temperature of the 
sample under study or energy changes of the sample with respect to time. Them1al 
10 
analysis includes thermogravimetry (them1ogravimtric analysis, TGA), differential 
thermal analysis (DT A) and differential scanning calorimetry (DSC). DSC is frequently 
a preferred thermal analytical technique because of its ability to provide detailed 
infomrntion about both the physical and energetic properties of a substance (23) . DSC 
is very closely related to TGA, but differs only in that the sample and reference 
container are not contagious, but are heated separately by individual coils that are 
heated (or cooled) at the same rate. Platinum resistance thermometers monitor the 
temperature of the sample and the reference holders and electronically maintain the 
temperature of the two holders constant. If a thermodynamic event occurs which is 
either endothermic or exothermic, the power requirements for the coils maintaining the 
constant temperature will differ. This power difference is plotted as a function of the 
temperature recorded by the programming device. Unlike DT A, in DSC the amount of 
heat put into the system is exactly equivalent to the amount of heat absorbed or 
liberated during a specific transition (transition energy). Melting of a drug is one of the 
examples of the endothermic transition. Exothermic transitions, such as conversion 
from one polymorph to a more stable polymorph, can also be detected. Lack of a 
melting peak in the DSC of a solid dispersion indicates that the drug present in 
amorphous rather than crystalline form. 
1.4.2 X-ray diffraction: 
Powder X-ray diffraction analysis is employed in the characterization of crystalline 
structure. X-rays are high-energy electromagnetic radiations of short wavelength. 
Diffraction is the scattering of x-rays in a few specific directions by the crystals. The 
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( scattering and diffraction is caused by the interaction with electrons. When an X- ray 
beam hits a crystal surface at angle 0, a portion of it is scattered by the layers of atoms 
at the surface. The unscattered portion of the beam penetrates to the second layer of 
atoms where again a fraction is scattered, and remainder passes on the third layer. 
In powder X-ray diffraction analysis the crystallinity of the sample is reflected by a 
characteristic fingerprint region in the diffraction pattern. Owing to specificity of the 
finger print region, crystallinity of the drug can be separately identified from that of the 
carrier. However, crystallinities of fewer than 5-10% cannot be determined with X-ray 
diffraction (23). 
1.4.3 Solubility and Dissolution studies: 
Solubility and dissolution studies are of prime importance in accessing the success of 
these approaches. As the goal of preparing solid dispersions is to improve solubility 
and consequently, dissolution of poorly water-soluble drugs, the release rate 
experiment results are very important. Dissolution studies help in understanding the 
rate of dissolution differences between drug, physical mixture, solid dispersions and 
solid solutions. Comparison of results with those for pure drug powder and a physical 
mixture of the drug in a carrier can help indicate the mechanism by which the carrier 
improves dissolution. 
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1.5 Solutol HS ® 
Solutol HS is a Polyethylene glycol 660 12-hydroxystearate. It is a yellowish white 
paste at room temperature that becomes liquid at 30° C. It consists of polyglycol mono 
and di-esters of 12-hydroxy-stearic acid (lipophilic part) and about 30% of free 
polyethylene glycol (hydrophilic part) (24). It dissolves in water, ethanol and 2-
propanol to form a clear solutions. Its solubility in water decreases with increasing 
temperature. It has high chemical stability. 
It is useful for the manufach1re of aqueous parenteral preparations with vitamin A, D, 
E, K and a number of other lipophilic pharmaceutical active ingredients (25). It has 
been also used to increase the solubility and consequevently bioavailability of 
Cyclosporin A (26). It has been utilized to improve the stability of parenteral emulsions 
too (27). 
H(O - CH2 - CH2)x - o, 
n 
0 
0 
II 
H(O - CH2 - CH2)y - O"'C 
OH 
o, 
c-o 
OH 
FIGURE 3: CHEMICAL STRUCTURE OF SOLUTOL HS 
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1.6 Vitamin E TPGS ® 
Vitamin E TPGS is prepared by the etherification of polyethylene glycol 1000 to the 
acid group of crystalline d-a tocopheryl acid succinate. It is also called as d-a 
tocopheryl polyethylene glycol 1000 succinate. The molecular weight of Vitamin E 
TPGS is approximately 1513. It is practically tasteless and is a yellowish to off-white 
solid. It is mainly used to absorb Vitamin E easily from the gastrointestinal tract (28). 
Vitamin E TPGS is water-soluble while other forms of Vitamin E are fat-soluble. 
0 
(CH2CH2CH2 Cr-I)3CH3 
"'cH CH3 
3 
coo 
I 
CH2 I CH::;: 
fH::: 
C 00( CH2 CH2 O)r.H 
FIGURE 4: CHEMICAL STRUCTURE OF VITAMIN E TPGS 
Along with assisting in vitamin E absorption, the water solubility of Vitamin E TPGS 
results in a product, which is quite stable and does not hydrolyze under normal 
conditions (29). It is used in the preparation of nanospheres (30) of paclitaxel, for 
enhancement of intestinal absorption of vancomycin (31 ), to increase solubility of 
cyclosporin (32), and to fom1 hot-melt extrudates with selected drugs (33). 
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1.7 Poloxamer 188 NF ® (Pluronic F68) 
Poloxamer 188 is water-soluble block copolymer of the general formula, 
CH3 
I 
HO- (CH2-CH2-0) x - (CH2-CH-O) y- (CH2-CH2-0) x - H 
Where x = approx. 79 and y = approx. 28 
FIGURE 5: STRUCTURAL FORMULA OF POLOXAMER 188 
It contains approximately 80% Polyoxyethylene block and its average molecular 
weight is 8250. It is a white to slightly yellowish waxy substance in the form of 
micropearls having slight odor (34). It is readily soluble in ethanol and water. It has 
widespread industrial application in detergency, dispersion stabilization, foaming, 
emulsification, lubrication, etc. In addition, they are used in specialized applications 
such as for the solubilization and controlled release of drugs. 
Poloxamer 188 NF is useful in improving the dissolution rate of many hydrophobic 
drugs such as digitoxin and digoxin (35), nifedipine (36). Also, Its solubilizing effect 
does not depend on the fom1ation of micelles . 
1.8 Lipocol C 10 
Lipocol C 10 is a white waxy solid and has a characteristics bland odor. It has a 
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( Vitamin E TPGS i.e. 12.9. It is used to deduce the effect of surfactant property of 
Vitamin E TPGS in this sh1dy. 
1.9 Microfluidization 
Microfluidization is a process largely used to prepare microemulsions (37) and 
liposomes (38). Microfluidization is used to study the effect of shear stress on the 
properties of a solid dispersion. It employs a the submerged jet principle in which two 
fluidized streams interact at ultrahigh velocities in precisely defined microchannels 
within the interaction chambers. 
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( Statement of Problem: 
According to Biopharmaceutical classification of system (BCS), Carbamazepine is 
Class II drug. The BCS is a scientific framework for classifying drug substances based 
on their aqueous solubility and gastro-intestinal permeability. Carbamazepine falls 
under Class II category that means it has high permeability but solubility is low and as 
a result absorption may be low, also. 
It has also been shown that carbamazepine 1s characterized by low and erratic 
absorption from the gut. The conventional carbamazepine tablet yields peak plasma 
concentration varying from 4 to 32 hours. This irregular and delayed absorption of 
carbamazepine is attributed to slow dissolution. Thus, dissolution is the main rate-
limiting step for the absorption of carbamazepine. If the solubility of carbamazepine is 
enhanced then dissolution rate would also increase and subsequently bioavailability 
too. 
Objective of study: 
Carbamazepine is used for epilepsy, trigeminal neuralgia and bipolar disorder. It is 
neutral and lipid soluble in nature, with very poor water solubility and dissolution rate. 
In order to increase its solubility and di ssolution, solid dispersions will be prepared 
using Solutol HS, Vitamin E TPGS, Poloxamer 188 and Lipocol C 10 respectively. The 
solid dispersion will be prepared by the melt or fusion method. For comparison 
purposes, physical mixtures of the same ratios will be prepared by simple mixing. The 
solvent evaporation process will be also utilized to study varied effect on the solid-state 
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( of the drug. All preparations will be characterized by differential scanning calorimetry 
(DSC), powder X-ray diffraction (XRD), solubility and dissolution studies. The 
solubility studies will be carried out in distilled water and solubility measurements will 
be done utilizing an UV-visible spectrophotometer. A USP dissolution apparatus II will 
be used to perform dissolution studies. 
There may be some positive effect of shear stress on the solubility of carbamazepine in 
presence of polymer. To ascertain this fact, the Microfluidizer will be used to study the 
effect of shear stress on the solid dispersions . 
The objectives of this research project, therefore, can be summarized as: 
A) To enhance the solubility of the carbamazepine using selected water-soluble 
polymers and a solid dispersion technique. Also, to analyze the effect of solubility on 
the dissolution rate of Carbamazepine. 
B) To evaluate the effect of microfluidization of the solid dispersion of drug on its 
solubility. 
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( SECTION II 
\ 
Manuscript I 
Enhancement of Carbamazepine Solubility using selected water-soluble polymers 
and a solid dispersion technique 
Abstract: 
Solubility of any drug m the gastrointestinal tract has profound a effect on the 
bioavailability of that particular drug in the body. Carbamazepine is a drug of choice 
in the treatment of epilepsy, trigeminal neuralgia, bipolar disorder and acute mania. 
According to Biopharmaceutical Classification System (BCS), it is a Class II drug, 
which means it has low solubility and high permeability. It is hydrophobic in nature 
and has a poor dissolution rate. It has been shown that conventional Carbamazepine 
tablets show variable peak plasma concentrations from 4- 32 hours, which in tum 
gives variable Bioavailability. In order to increase its water solubility and the 
dissolution rate, solid dispersions were prepared using water-soluble polymers namely 
Solutol HS, Vitamin E TPGS, Poloxamer 188 and Lipocol C 10. Solid dispersions 
with these polymers were prepared by the fusion method. For solubility studies, a 
fixed ratio of 900 mg: 100 mg (drug: carrier) was used. Physical mixtures and 
recrystallized mixtures of the same ratio were also used for comparison purpose. For 
dissolution studies, optimized ratios of solid dispersions were used. All preparations 
were characterized by Differential Scanning Colorimetry (DSC) and powder X- ray 
diffraction studies. Microfluidization studies were also conducted to determine the 
effects of shear stress on the solubility of the solid dispersions. The Solubility of 
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( Carbamazepine improved considerably with the solid dispersions for all the selected 
polymers as compared to physical mixtures and recrystallized mixtures. 
Microfluidization studies showed initial spike in the solubility, then, rapid decline 
back to equilibrium solubility. It showed no significant effect of shear stress on the 
equilibrium solubility of solid dispersions of Carbamazepine. The dissolution rate of 
the drug was also improved with the solid dispersions as compared to physical 
mixtures. DSC and X-ray diffraction studies showed no significant change in the 
crystallinity of the drug at a ratio of 900 mg: 100 mg. However, an increased ratio of 
polymer (20:80) showed significant change in the crystallinity of the drug. Vitamin E 
TPGS was found to be best polymer of all the polymers used to increase the solubility 
as well as dissolution rate of the Carbamazepine. The improved solubility may be 
attributed deagglomeration of fine particles, and presence of carbamazepine as very 
small crystallites within the dispersion. Water-soluble polymers might have formed a 
complex with Carbamazepine, which is enough to inhibit the conversion of 
Carbamazepine anhydrous to dihydrate, which is the sole reason for low solubility of 
Carbamazepine. 
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( 2.1 Introduction: 
The important requirement to achieve absorption of a poorly water-soluble drug from 
the GI tract and achieve a desired bioavailability is that the drug should be in solution 
in the GI tract. A poorly water-soluble drug is the one whose dissolution in the GI 
fluid under normal conditions takes a longer time than its transition through the 
absorption sites in the GI tract (1). The solubility enhancement of such a poorly 
water-soluble drug and in tum increasing its oral bioavailability drugs poses one of the 
most challenging aspects of the drug development. Although salt formation, 
decreasing particle size and other methods are commonly used to increase the 
solubility of the drugs, there are practical limitations with these techniques and thus, 
the desired bioavailability enhancement may not always be achieved (2). Today 
among the many methods available, a solid dispersion system in which drug is 
dispersed in water-soluble matrices either molecularly or as fine particles has gained 
attention in recent years. It has shown promising results in increasing the dissolution 
as well as bioavailability of many poorly water-soluble drugs (3). 
Although a search of the literature revealed that many articles on solid dispersions, 
very few research articles are available on the utilization of solid dispersions to 
enhance the solubility of carbamazepine and subsequently dissolution and 
bioavailability. Attia and Habib, 1985 (4) prepared solid dispersions with sugars to 
enhance the dissolution as well as bioavailability of carbamazepine. Different classes 
of nonionic surfactants as well as bile salts were used by Samaha and Gadalla, 1987 
(5) to study their solubilization effect on carbamazepine and found a marked increase 
in solubility with all eight nonionic surfactants used. They also found that increasing 
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( the concentration of the bile salts increased the solubilized amount of carbamazepine. 
Luthala, S., 1990 (6) studied the effect of benzalkonium chloride, a cationic surfactant, 
on the growth of carbamazepine crystals in aqueous suspensions and also the effect of 
this surfactant on the solubility of carbamazepine in water. The growth of 
carbamazepine crystals, which is initiated by a transition from the anhydrous form to a 
dihydrate, is caused by the differences in the solubilities of the two forms with the 
anhydrate demonstrating at least 2.4 times greater solubility than the dihydrate. 
Benzalkonium chloride was found to increase the apparent solubility of carbamazepine 
in the system. Habib et al. , 1993 (7) studied the development of a carbamazepine and 
phospholipid solid dispersion formulation to improve dissolution characteristics of 
carbamazepine. Al-Meshal et al., 1993 (8) formed complexes of carbamazepine with 
cyclodextrins and found the inclusion complex to augment the bioavailability of 
carbamazepine. Zerrouk et al., 2001 (9) investigated the effects of solid dispersion on 
the solubility, the dissolution rate and the pharmacokinetic profile of carbamazepine. 
They found that solubility studies showed a linear increase in carbamazepine solubility 
with increasing PEG 6000 concentration. 
The objective of this study was to increase the water solubility of carbamazepine by 
preparing solid dispersions using Solutol HS, Vitamin E TPGS, Poloxamer 188 or 
Lipocol C 10. These studies include preparation and characterization of the solid 
dispersions and evaluation of the effect of the shear stress of the solid dispersions on 
the solubility of Carbamazepine. A microfluidizer is used to assess the effect of shear 
stress on the solubility of solid dispersions. Also, to know exact mechanism of 
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solubility enhancement, solid dispersions are prepared with Lipocol C 10 are prepared 
and analyzed in the same manner. 
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( 2.2 Materials: 
2.2.1 Chemicals 
Hi-Tech Pharmacal, NY, provided micronized Carbamazepine. Solutol HS and 
Pluronic F68 (Poloxamer 188 NF) were obtained from BASF Corporation (Mount 
olive, NJ). Vitamin E TPGS and Lipocol C 10 were purchased from Eastman 
Chemicals (Kingsport, TN) and Lipo Chemicals (NJ) respectively. Sodium chloride 
(Fisher Scientific, Fair Lawn) and hydrochloric acid (Fisher Scientific, Fair Lawn) 
were used to prepare simulated gastric fluid dissolution medium. Methanol and 
acetone were used to recrystallize the mixture of carbamazepine with various 
polymers. Purified de-ionized water was prepared using Milli Q50 (Millipore, 
Bedford, MA) purification system. All chemicals used were of analytical grade. 
2.2.2 Instruments 
The analysis of all the samples was performed usmg HP 845 lA Diode Array 
Spectrophotometer. Microfluidization studies were conducted usmg M-11 OS 
Microfluidizer® Processor (Microfluidics Corporation). Dissolution studies were 
conducted using USP Dissolution Apparatus II (Vankel Dissolution System model). 
Differential Scanning Calorimetry (DSC); (TA Instruments QlOO), Microchip based 
Powder X-ray Diffraction instrument is used for X-ray diffraction studies. 
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( 2.3 Methods: 
2.3.1 Preparation of physical mixtures 
The drug and carriers were passed through a 40-mesh screen and mixed thoroughly in 
a mortar and pestle. For solubility studies, a fixed ratio of drug and carrier was used 
(900 mg: 100 mg). For the microfluidization studies, a drug to carrier ratio of 20:80 
was used. For dissolution studies, various ratios were prepared depending on the 
results of the optimization study of the solid dispersions. 
2.3.2 Preparation of Solid dispersions 
The respective polymer was heated at about 60° C in an oven, until it melted 
completely. The drug was added to the molten polymer and mixed thoroughly. The 
mixture was cooled to ambient conditions, milled and passed through a 40-mesh 
screen. The same ratios used for the physical mixtures, were used for the preparation 
of the solid dispersions. 
2.3.3 Preparation of Recrystallized Mixtures 
The drug and polymer were weighed (900 mg: 100 mg) and dissolved by sonication in 
1 O ml of a 1: 1 mixture of acetone and methanol. The solution was filtered under 
vacuum and then transferred to an evaporating dish. The solvents were allowed to 
evaporate at room temperature under the vacuum hood and then the samples were 
transferred to a dessicator and further dried for 24 hours or until no further loss in 
weight occurred. 
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( 2.3.4 Preparation of Microfluidized Mixtures. 
The respective polymer was heated to 60° C in an oven, until it melted completely. 
The drug was added to the molten polymer and mixed thoroughly. The mixture was 
then passed through the microfluidizer preheated at 60° C. Microfluidizer was 
operated at pressure gauge set to 40 psi. The solution was then passed through the 
equipment for 10 strokes of the pump and collected from the outlet. 
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2.4 Solubility Measurements: 
Solubility studies of Carbamazepine were performed in water, for a period of 48 hours 
with sample analysis at nine time intervals according to the method of Connors and 
Higuchi (10). The 48-hour time duration was selected since it allowed the drug to 
reach equilibrium solubility. An excess amount of the drug in the medium ensured 
equilibrium during the 48-hour period. The studies were conducted at room 
temperature (25° C). The solution was filtered through a 0.45 µ pore size filter. The 
solution concentration was measured using UV-Visible spectrophotometer at 285 nm. 
2.5 Dissolution Studies: 
Dissolution was studied usmg a USP Dissolution Apparatus II with 900 ml of 
simulated Gastric Fluid without pepsin at pH 1.3 ± 0.05 as a dissolution medium at 
3 7° C and a paddle speed of 50 RPM. Accurately weighed amounts of the solid 
dispersions or physical mixtures, corresponding to 20 mg of carbamazepine, were 
added to the dissolution media. As per guidance given in FDA dissolution manual, the 
samples were placed into an AAA size gelatin capsule. Samples were drawn at 
different time intervals and assayed for drug content using UV NIS spectrophotometer 
with reference to a suitably constructed standard plot at 285 nm. The withdrawn 
volume of sample media was replaced with a fresh media. The studies were conducted 
at room temperature (25° C). 
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( 2.6 Differential Scanning Calorimetry analysis 
A Differential Scanning Calorimeter (DSC) equipped with a liquid nitrogen-cooling 
accessory was used. Samples (5-1 Omg) were prepared in hermitically sealed pans. The 
pans were crimped with the instrument sealer for the solid samples. The samples were 
scanned at a heating rate of 10° C/min. from 0° C to 220° C. Data were treated 
mathematically using DSC TA universal analysis program. 
2.7 Powder X-ray Diffraction (XRD): 
Various samples were analyzed by Powder X-ray diffraction usmg Fe anode to 
determine the crystalline state of the drug in the solid dispersions. The XRD pattern 
was collected in the angular range of 6 < 2 8 < 76°in step scan mode. A current of 10 
miliamperes and a voltage used of 34 kW was used. The scans are conducted at room 
temperature and pyrolytic graphite is used as a filter. 
2.8 Statistical Analysis 
A two factorial design is used to study the effect of the different processes and 
polymers on the solubility of the drug. In this study, we have used a 4 x 3 factorial 
design, that is, we have 2 factors , one with 4 levels and the other with 3 levels. The two 
factors are polymer (C 1) and process (C2) with 4 and 3 levels respectively. The two 
independent variables, their levels and their values are summarized in Table 2. 
Therefore, the number of treatment groups would be 4 x 3 = 12 groups (Table 3). Data 
for each representative group is generated in triplicates; hence, we have 36 
observations. Solubility was the response parameter. All the statistical and regression 
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( analysis procedures in the response parameters were performed using the Minitab ® 
software package. Statistical analysis was carried out which includes the analysis of 
variance (ANOV A) to determine the significance of each independent variable 
(process, polymer), two-way interactions (process-polymer) (10). The general linear 
model used for the experimental design was: 
The Student-Newman-Keuls Test with SAS software was performed to determine the 
best polymer process combination that would give the best possible results to enhance 
the solubility. 
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( 2.9 Results and Discussion: 
2.9.1 Solubility Measurements: 
The solubility determinations were carried out using an excess amount of a drug at a 
fixed ratio of drug to polymer of 900 mg: 100 mg with three replications according to 
the method of Connors and Higuchi (11). Solutol HS, Vitamin E TPGS, Poloxamer 
188 and Lipocol C 10 were used for this study. In solubility determinations the 
concentration in solution depends on the drug's solubility. Excess drug accounts for 
any loss that may occur in solution, whereby more drug is released from the suspended 
particles so that the amount of dissolved drug remains constant. This concentration is 
the drug ' s equilibrium solubility in a particular solvent at a particular temperature (12). 
The initial rate of solubilization of the drug varies hyperbolically with time. During the 
initial time period, the drug goes into solution continuously, increasing the 
concentration of drug linearly. As the time increases, more and more drug goes into 
solution, until the solution is saturated with the drug, and equilibrium solubility is 
observed. 
Physical mixtures, solid dispersions and recrystallized mixtures were prepared as per 
the methods described. Accurately weighed quantity of each sample were weighed and 
transferred to glass vials. Added 10 ml of water into the vials and vials were allowed to 
shake for 48 hours on a Burrell wrist shaker. 2ml of samples were collected at 10, 30, 
45 , 60, 120, 360, 720, 1440, and 2880 minutes with the replacement of 2ml fresh 
water. Samples were filtered and analyzed using UV-Visible spectrophotometer at 285 
nm after dilution. The solubility profile of the untreated drug, physical mixtures, solid 
dispersions and recrystallized mixtures were examined. The solubility profiles of 
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( Carbamazepine with Saluto! HS, Vitamin E TPGS, Poloxamer 188 and Lipocol C 10 
are shown in Figures 6, 7, 8, & 9 respectively. The physical mixtures of the drug and 
the three polymers were tested for any positive effect on the solubility of the drug in 
the presence of polymers. A look at solubility profiles shows a 10-50 µg/ml increase 
in solubility for all the physical mixtures as compared to the solubility of 
carbamazepine alone at any given time point. However, this was not a significant 
increase in solubility and hence can be considered equivalent to untreated drug for all 
practical purposes. All the polymers increase the solubility of carbamazepine when 
they were incorporated as Solid dispersions. It is evident that Vitamin E TPGS when 
used in the solid dispersions shows greater increase in solubility as compared to other 
three polymers (Figure 10). There is an approximate 500% increase in solubility with 
the use of Vitamin E TPGS, and 200-400%-fold increases with the use of Solutol HS, 
Poloxamer 188 and Lipocol C 10, which is shown in Table 2. 
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TABLE 2: COMPARISON OF SOLID DISPERSIONS OF CARBAMAZEPINE WITH 
SOLUTOL HS, VITAMIN E TPGS, POLOXAMER 188, AND LIPOCOL C 10 (90:10) 
Time CBZ (ug/ml) Sol (SD) Vit. E (SD) Pol. (SD) LC (SD) J_minl J_u_g_/m!2_ J_u_g_/m!2_ J_u_g_/m!2_ J_u_g_/m!2_ 
0 0 0 0 0 0 
10 149.00 449.22 432.40 253.37 481.50 
30 100.97 499.13 544.73 286.69 494.95 
45 106.39 484.35 627.34 277.27 527.35 
60 101 .82 459.43 603.69 258.08 509.30 
120 93.05 464.80 578.62 231.38 361 .20 
360 103.83 462.77 567.84 269.12 380.15 
720 94.15 474.10 532.68 262.54 355.80 
1440 106.28 438.62 534.78 255.96 360.60 
2880 85.00 454.87 535.89 241 .00 344.65 
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FIGURE 10: SOLUBILTY PROFILE OF CARBAMAZEPINE AND ITS 
SOLID DISPERSION WITH SOLUTOL HS, VITAMIN E TPGS, 
POLOXAMER 188 AND LIPOCOL C 10 (90:10) 
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DSC scan of the Carbamazepine represented in Figure 11 shows a distinct melting 
endothem1 at around 192° C. Pure carbamazepine shows a small melting endotherm at 
176° C followed by second endotherm at around 192° C. These two endotherms 
correspond to form III and I of Carbamazepine respectively. DSC scans of Solutol HS, 
Vitamin E TPGS, Poloxamer 188 and Lipocol C 10 with characteristic endotherm for 
each of the polymers are depicted in Figures 12 - 15 . The DSC data carried out on the 
physical mixtures (Figures 16 - 19) does not show any changes in the melting 
endotherms of the mixture, from that of the untreated drug. Distinct endotherms for 
drug as well as for the polymers can be seen in those scans. Thus, we can safely 
conclude that there is no fom1 of chemical interaction between the drug and any of the 
polymers in their physical mixtures. 
The DSC scans carried out for solid dispersions of the carbamazepine with each 
polymers also shows the same pattern of endotherms as that of physical mixture 
(Figures 20 - 23). 
40 
( 
Sample: Carbamazepine 
Size: 4.7000 mg 
Method: Ramp 
Comment:-
ol~ I 
-= 
s 
:;:: 
-2-< 0 
LL 
cu 
Q) 
:::r:: 
4-
-6 
0 
Exo Up 
DSC 
182.09'C 
-0.2213W/g 
50 100 150 
Temperature (°C) 
File: C: ... \Minallzicaiagar.024_Ren0105041460 
Operator: PZ Lian 
Run Date: 19-Feb-0412:44 
Instrument: DSC 0100 V3.5 Build 175 
203.71 'C j_-0317"/10 
~ 
I 
\I 
I 
\1 
+ 
t 
~192.16'C 
-5.131W/g 
200 250 
Universal V3.58 TA Instruments 
FIGURE 11: REPRESENTATIVE THERMOGRAM SHOWING MELTING 
ENDOTHERM OF CARBAMAZEPINE 
41 
( 
Sample: Plain Solu. HS -15 
Size: 0.0000 mg 
Method: Ramp 
Comment:-
s: 
E:: 
-
:;:: 
0 
LL 
"' Q) 
:::c 
2-
a-
1 
-2-< 
-4 ~ 
-6 
-8 
1 
-10 -
0 
Exo Up 
t 25.81 'C 
-9.524mW 
50 
DSC 
100 
Temperature (°C) 
File: C: ... \Minal\zicaiagar.024_Ren0105041434 
Operator: PZ Lian 
Run Date: 06-Jan-04 12:59 
Instrument: DSC Q100 V3.5 Build 175 
150 200 
Universal V3.5B TA Instruments 
FIGURE 12: REPRESENTATIVE THERMOGRAM SHOWING MELTING 
ENDOTHERM OF SOLUTOL HS 
42 
( 
Sample: Plain Vt. E TPGS 
Size: 4.5000 mg 
Method: Ramp 
Comment: -
-1-
-en 
s: 
:;;: 
-2-t ~ 
LL 
ro 
Cl) 
I 
-3"' 
,-----. 
t 36.71'C 
-3.233W/g 
DSC 
File: C: ... \Minal\zicaiagar.024_Ren0105041433 
Operator: PZ Lian 
Run Date: 06-Jan-04 12:30 
Instrument: DSC 0100 V3.5 Build 175 
1 .-----,,---,-~-,-~-.----.~-,.-~--,--~~---.~--r-~-,---~r-----,-~--r-~-,-----, 
0 
E.xo Up 
50 100 
Temperature (°C) 
150 200 
Universal V3.5B TA Instruments 
FIGURE 13: REPRESENTATIVE THERMOGRAM SHOWING MELTING 
ENDOTHERM OF VITAMIN E TPGS 
43 
Sample: Polaxamer188 
Size: 5.0000 mg 
Method: Ramp 
Comment:-
41.20'C 
"T' 
0 (___/ l 
= 
~ -2-
LL 
ro 
Q) 
:r: 
-4 
I 
\ I 
\ I 
I 
I I 
I 
I 
DSC File: C: ... \Sameerlzicaiagar.024_ Ren0105041461 Operator: PZ Lian 
Run Date: 19-Feb-04 13:27 
Instrument: DSC 0100 V3.5 Build 175 
66.92'C 
~~--0.2-78-2W-~ ~~~~-------~~ 
55.74'C 
-4.052W/g 
-6--r---.----r---.,.~.,.---,------r---.,.~.,.---,------r---.,.~.,.---,------r---,~.,.--~-,---,~ 
0 50 100 150 200 250 
Exo Up Temperature (°C) Universal V3.5B TA Instruments 
FIGURE 14: REPRESENTATIVE THERMOGRAM SHOWING MELTING 
ENDOTHERM OF POLOXAMER 188 
44 
( 
Sample: Plain LC 10 
Size: 12.0000 mg 
Method: Ramp 
Comment:-
or 
~ 
!~ 
I \ 
s:: 
1 ;;; 
S! 
_, j 
LL 
en 
CIJ I I 
l 
'1 
l 
-3 
0 
Exo Up 
I I 
I 
I 
37.90'C 
+ -2.794W/g 
50 
DSC 
100 
Temperature (°C) 
File: C: ... \Minallzicaiagar.024_ Ren0105041457 
Operator: PZ Lian 
Run Date: 06-Feb-0412:19 
Instrument: DSC Q100 V3.5 Build 175 
150 200 
Universal V3.58 TA Instruments 
FIGURE 15: REPRESENTATIVE THERMOGRAM SHOWING MELTING 
ENDOTHERM OF LIPOCOL C 10 
45 
( 
Sample: Cbz: Solutol(90:10) PM 
Size: 18.1000 mg 
Method: Ramp 
Comment:-
0.0 \ f I 
\ = -0 5 j s: 
24.43'C 3 
-0.3438W/g E 
LL 
"' O..J
-1 0 ::r: 
-1 5 • 
DSC 
File: C: ... \Sameer\zicaiagar.024_Ren0105041468 
Operator: PZ Lian 
Run Date: 23-Mar-04 12:25 
Instrument: DSC Q100 V3.5 Build 175 
I 
\ I I 
I 
I 
I I 
I I 
190.29'C 
~ 
-1 .582W/g 
-2.0 ~~~-~~~-~~-~~~-~~~-~~-~~~-~_, 
0 50 100 150 200 250 
Exe Up Temperature ('C) Universal V3.5B TA Instruments 
FIGURE 16: REPRESENTATIVE THERMOGRAM OF PHYSICAL 
MIXTURE OF CARBAMAZEPINE AND SOLUTOL HS (90: 10) 
46 
Sample: Cbz: Vtt E TPGS(90: 10) PM 
Size: 18.9000 mg 
Method: Ramp 
Comment: -
1 { 
O.C • 
-0.2~ 
O'l 
s: -0 4 
:;: 
0 
LL. 
"' 
-06. 
"' :::r:: 
-0 8 
-k--_38.59'C 
-1 o~ -0.9507W/g 
DSC File: C: ... \Sameer\zicaiagar.024 _ Ren0105041467 Operator. PZ Lian 
Run Date: 23-Mar-04 11 :54 
Instrument: DSC 0100 V35 Build 175 
\ 
189.17'C 
;"~' 
-·2 ~~~~~~~~~~~~~~~~~~~~~~~~ 
0 50 100 150 200 250 
Exo Up Temperature ('C) Universal V3.SB TA Instruments 
FIGURE 17: REPRESENTATIVE THERMOGRAM OF PHYSICAL 
MIXTURE OF CARBAMAZEPINE AND VITAMIN E TPGS (90: 10) 
47 
Sample: Cbz Poloxamer(90:10) PM 
Size: 12.9000 mg 
Method: Ramp 
Comment:-
o-11 I 
_/ 
+ +--
:: 
<) \ 
LL 
ro 
ID 
:r: 
-2 ... 
53.81 'C 
-0.6111W/g 
-0.611 1W/g 
DSC File: C: ... \Sameerlzicaiagar.024_Ren0105041466 Operator: PZ Lian 
Run Date: 23-Mar-04 11 :22 
Instrument: DSC 0100 V3.5 Build 175 
I 
I 
I 
I 
I 
i---
1 192.60'C 
-2.471W/g 
-3-~~~~-~~~-~~~-~~~~-~~~-~~~~ 
0 50 100 150 200 250 
Exo Up Temperature (°C) Universal VJ.SB TA Instruments 
FIGURE 18: REPRESENTATIVE THERMOGRAM OF PHYSICAL 
MIXTURE OF CARBAMAZEPINE AND POLOXAMER 188 (90: 10) 
48 
( 
Sample: Cbz: LC10(90:10) PM 
Size: 20.4000 mg 
Method: Ramp 
Comment: -
~oJ 
I~ I 
c ,j 
= 
3:: 
:;: 
~ 0 LL 38.22'C 
"' 
-0.7653W/g 
Q) 
:c 
-1') 
. ) 
-2 0 
0 50 
Exo Up 
DSC 
100 150 
Temperature (°C) 
File: C: ... \Sameer\zicaiagar.024_Ren0105041469 
Operator: PZ Lian 
Run Date: 23-Mar-0412:56 
Instrument: DSC 0100 V3.5 Build 175 
r 
I 
\ / 
I 
1, 
11 
I 
191.41 'C 
-1.793W/g 
~ 
200 250 
Universal V3.5B TA Instruments 
FIGURE 19: REPRESENTATIVE THERMOGRAM OF PHYSICAL 
MIXTURE OF CARBAMAZEPINE AND LIPOCOL C 10 (90: 10) 
49 
Sample: Cbz: Solutol(90:10) SD 
Size: 16.8000 mg 
Method: Ramp 
Comment:-
DSC File: C: ... \Sameerlzicaiagar.024 _Ren01050414 73 Operator: PZ Lian 
Run Date: 23-Mar-04 14:59 
Instrument: DSC 0100 V3.5 Build 175 
G.5 --------------------------
1 
00~ 
l 
1 \ -0.51 i = 
s: 25.17'C 
-0.3461W/g 
s: 
_1 0-l 0 
LL 
ro 
(lJ 
:r: 
-· 5 
-2 0 
o 50 
ExoUp 
\ 
\ 
I 
I 
100 150 
Temperature (°C) 
----I I 
I 
191 .78'C 
r---2093W/g 
200 250 
Universal VJ.SB TA Instruments 
FIGURE 20: REPRESENTATIVE THERMOGRAM OF SOLID 
DISPERSION OF CARBAMAZEPINE AND SOLUTOL HS (90: 10) 
50 
Sample: Cbz: Vit E TPGS(90:10) SO 
Size: 20.6000 mg 
Method: Ramp 
Comment:. 
DSC File: C: . ..\Sameer\zicaiagar.024_ Ren0105041470 Operator: PZ Lian 
Run Date: 23-Mar-04 13:27 
Instrument: DSC 0100 V3.5 Build 175 
0.5-------------------------, 
001~ 
1 II 
I 
= 
-O.SJ !\ I 
s: 
3:: 
0 
LL 
"" Q) 
:::c 
I 
I 
' 
\ 
\ I 39.34'C \ 
\ I -1 o~ -0.7607W/g 
\I 
-1.5 ~ 11 
190.29'C 
~-1.717W/g 
-2 0 -,.---,---,---,----.---,-.---,---.-~---.-..---,---,---,----.---,-.---,---.---; 
0 50 100 150 200 250 
ExoUp Temperature (°C) Universal V3.58 TA Instruments 
FIGURE 21: REPRESENTATIVE THERMOGRAM ENDOTHERM OF 
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FIGURE 22: REPRESENTATIVE THERMOGRAM OF SOLID 
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X-Ray Diffraction studies can confirm the physical state of carbamazepine in physical 
mixtures as well as in solid dispersions too. All the solid dispersions and physical 
mixtures show the presence of distinct peaks characteristics of crystallinity. Pure 
carbamazepine shows peaks at the region from 150-500 on the X-ray scan represented 
in Figure 24. Solutol HS, Vitamin E TPGS, Poloxamer 188 and Lipocol C 10 show 
distinct peaks in the region from 250-500 on the X-ray Scan (Figures 25 - 28). The 
characteristics peaks of carbamazepine were also evident in all the physical mixtures 
(Figures 29 - 32). Thus, simply mixing of the drug and polymers did not change the 
physical state of either of the components. Figures 33 - 36 show X-ray diffraction 
pattern of carbamazepine solid dispersions. Solid dispersions of carbamazepine show 
characteristics peaks of carbamazepine. We can conclude that solid dispersion also did 
not change the physical state of either of the components. 
From the DSC and X-ray data we can safely conclude that there 1s no change m 
crystallinity pattern of either of the components. 
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( One of the major reasons for the poor solubility of carbamazepine is conversion of 
anhydrous form to the dihydrate form when it comes into contact with water (13,14). 
The solubility of anhydrous carbamazepine is approximately twice that of it dihydrate 
( 15). Polymers have got polar and non-polar ends in their structure and they can 
interact with the polar and non-polar group present in the carbamazepine structure. 
This way they can prevent the formation of dihydrate in aqueous solutions. It has been 
shown that some surfactants and polymers prevent the dihydrate formation of 
carbamazepine by micelle formation and also increase solubility to considerable extent 
(8). The presence of hydroxypropyl methylcelluose in sustained released tablets also 
has been shown to affect the dissolution of the drug due to its inhibitory effect on 
dihydrate formation ( 16). Recently, it was shown that hydroxypropyl cellulose 
inhibited the dihydrate formation of carbamazepine (17). Also, it has been show that 
solid dispersions with polyethylene glycol (PEG) have an inhibitory effect on dihydrate 
formation and an enhanced effect on the solubility of carbamazepine (18). 
In the present study, enhancement of solubility of carbamazepine can be attributed to 
different factors like wetting effect, the formation of amorphous carbamazepine, and 
presence of carbamazepine as very small crystallites within the dispersion, and 
inhibitory effect of polymers on the conversion of anhydrous to dihydrate 
carbamazepine. In physical mixtures of carbamazepine with all the polymers (Figures 6 
- 9), there is not a significant increase in solubility, which indicates that there is very 
low wetting effect of the polymers on the solubility enhancement of carbamazepine. 
The DSC scans (Figures 20 - 23) and X-ray scans (Figures 33 - 36) of solid dispersion 
of carbamazepine with different polymers are similar to the DSC (Figures 16 - 19) and 
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/ X-ray scans (Figures 29 - 32) of physical mixtures of carbamazepine with different 
I 
polymers. This tells us that there is less possibility of formation of amorphous 
carbamazepine as there is no change in melting endotherms or no change m 
crystallinity pattern. But increasing the polymer content showed formation of 
amorphous carbamazepine. This may tell us that there may be presence of 
carbamazepine as very small crystallites of carbamazepine within the mixture at low 
content of polymer. Lipocol C l 0 is used in this study to try to determine mechanism of 
solubility enhancement. Lipocol C l 0 is a surfactant with hydrophilic lipophilic 
balance (HLB) value of 13 .0, which has the same HLB value as that of Vitamin E 
TPGS ( 13 .2). A physical mixture of Lipocol C 10 confirms that there is no significant 
wetting effect to enhance the solubility of carbamazepine. A solid dispersion of 
I carbamazepine and Lipocol C 10 gives nearly a 4-fold increase in solubility profile of 
carbamazepine. So it can be confirmed that the drug may be forming a micellar 
solubilization when it is incorporated into solid dispersions which has confirmed by 
Luthala et al. Physical mixtures do not show any positive effect on the enhancement of 
the solubility of carbamazepine. DSC and X-ray diffraction scans do not show 
formation of amorphous carbamazepine within the system. But the solubility profiles 
of solid dispersions (Figures 6 - 9) show great enhancement of the solubility of 
carbamazepine. The only other possible reason that we can postulate for this 
enhancement of solubility of carbamazepine would be inhibitory effect of polymers on 
the conversion of anhydrous to dihydrate carbamazepine this can further be further 
proved from the literature (18). Also, there is greater solubilization observed with 
Vitamin E TPGS than Lipocol C 10, which can be attributed to individual inhibitory 
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( effect of respective polymers for the convers10n of anhydrous to dihydrate 
carbamazepine. Therefore, enhancement of solubility of carbamazepine may be largely 
attributed to presence of very small crystallites within the dispersion and individual 
inhibitory effect of respective polymers for the conversion of anhydrous to dihydrate 
carbamazepine. 
The ANOV A table (Table 5) summarizes the statistical analyses conducted. From the 
table we can see that the P-values for the polymer, process and the polymer-process 
interaction are lower than the a-value (0.05). Hence we can conclude that these three 
factors have a significant effect on solubility of the drug. 
The Student-Newman-Keuls Test Table analyses all the results according to 
statistically significant differences. It can be seen that solid dispersion with Vitamin E 
TPGS is statistically significantly different than that of all other results. Hence we can 
conclude that solid dispersion with Vitamin E TPGS gives higher enhancement of 
solubility as compared with other polymers 
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TABLE 3: LIST OF FACTORS, THEIR LEVELS AND VALUES 
FACTOR 
Polymer 
Process 
POLYMER 
1 SOLUTOLHS 
2 VITAMIN E TPGS 
3 POLOXAMER 188 
4 LIPOCOL C 10 
TYPE 
Fixed 
Fixed 
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LEVELS VALUES 
4 1 2 3 4 
3 1 2 3 
PROCESS 
1 PHYSICAL MIXTURE 
2 SOLID DISPERSION 
3 RECRYSTALLIZATION 
( 
TABLE 4: 4 x 3 (2-FACTOR) FULL FACTORIAL DESIGN 
Cl C2 
NO Polymer Process 
1 1 1 
2 1 2 
3 1 3 
4 2 1 
5 2 2 
6 2 3 
7 3 1 
8 3 2 
9 3 3 
10 4 1 
11 4 2 
12 4 3 
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TABLE 5: ANOVA TABLE SUMMARIZING THE STATISTICAL ANALYSES 
General Linear Model: Solublllty versus Polymer, Process 
Factor Type Levels Values 
Polymer fixed 4 1 2 3 4 
Process fixed 3 1 2 3 
Analysis of Variance for Solubility, using Adj'\.lste"d SS for Tests 
Source DF Seq SS Adj SS Adj MS F p 
Polymer 3 216859 ; 216859 72286 543.12 0.000 
Process 2 1226825 lf 26825 613412 4608.85 0.000 
Polymer* Process 6 119052 119052 19842 149.08 0.000 
Error 24 3194 3194 133 
-..J Total 35 15=115930 
w 
( 
TABLE 6: STUDENT-NEWMAN-KEULS TEST ANALYSES 
The SAS System 
Class 
x 
13 : 52 Saturday , March 27 , 2004 
The GLM Procedure 
Class Level Information 
Levels Values 
1 
13 1 2 3 4 5 6 7 8 9 10 11 12 13 
Number of observations 130 
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TABLE 6: STUDENT-NEWMAN-KEULS TEST ANALYSES (contd.) 
The SAS System 13: 52 Saturday , March 27 , 2004 2 
The GLM Procedure 
Dependent Variable : y 
Sum of 
Source DF Squares Mean Square F Value Pr > F 
Model 12 2724402 . 364 227033 . 530 30 . 32 < . 0001 
Error 117 876170 . 308 7488.635 
Corrected Total 129 3600572 . 672 
R- Square Coeff Var Root MSE y Mean 
0 . 756658 47 . 72989 86.53690 181 . 3055 
Source DF Type I SS Mean Square F Value Pr > F 
x 12 2724402 . 364 227033 . 530 30.32 <.0001 
Source DF Type III SS Mean Square F Value Pr > F 
x 12 2724402 . 364 227033 . 530 30 . 32 < . 0001 
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TABLE 6: STUDENT-NEWMAN-KEULS TEST ANALYSES (contd.) 
The SAS System 13 : 52 Saturday , March 27 , 2004 3 
The GLM Procedure 
Student - Newman - Keuls Test for y 
NOTE : This test controls the Type I experiment wise error rate under 
the complete null hypothesis but not under partial null hypotheses . 
Alpha 
Error Degrees of Freedom 
Error Mean Square 
0 . 05 
117 
7488 . 635 
Number of Means 2 3 4 5 6 7 
Critical Range 76.6442 91 . 8725 100 . 866 107 . 2304 112 . 1348 116 . 1123 
Number of Means 8 9 10 11 12 13 
Critical Range 119 . 4499 122 . 3200 124.8342 127.0685 129.0772 130 . 9005 
Means with the same letter are not significantly different . 
SNK Grouping Mean N x 
A 495.79 10 9 
B 418 . 73 10 6 
B 
B 381 . 55 10 3 
c 233 . 54 10 12 
D 125 . 50 10 8 
D 
D 102 . 43 10 11 
D 
D 101 . 78 10 5 
D 
D 94 . 05 10 1 
D 
D 90 . 60 10 4 
D 
D 87 . 63 10 10 
D 
D 87 . 10 10 2 
D 
D 72 . 86 10 13 
D 
D 65 . 41 10 7 
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2.9.2 Microfluidization Study 
In this study, the process of microfluidization has been used to assist in evaluation of 
the effect of shear stress on the solubility of the solid dispersions of the carbamazepine. 
The solubility profile of physical mixtures, solid dispersions and microfluidized solid 
dispersions were examined. For this study, a ratio used was 20:80 (drug:polymer) as 
there may be problem of blockage of instrument if we use large amounts of drug. As 
seen in figure (Figures 37 and 38), both solid dispersions and microfluidized solid 
dispersions bring about an increase in the solubility of carbamazepine at the same 
level. However, microfluidized solid dispersions show an initial spike in the solubility 
at around 30 minutes. It also shows there is a rapid decline in solubility till 6 hours, 
reducing the amount of drug dissolved to the solubility of carbamazepine after 48 
hours. This indicates that there must be rapid conversion of the amorphous (high 
solubility) form to its crystalline (low solubility) form due to high pressure and the 
high temperature generated during microfluidization. The solid dispersions are not 
showing a rapid conversion of amorphous form to crystalline form as compared to the 
microfluidized solid dispersions. The DSC scans (Figures 40 - 44) for the solid 
dispersions and microfluidized solid dispersions show an absence of the endotherms. 
This fact is further proved by XRD (Figures 46, & 47) data. A lack of a drug melting 
endotherm in solid dispersions usually suggests the presence of the drug in an 
amorphous fom1 within the dispersions. The DSC scan and X-ray scan data indicate 
that the higher solubility is due to the conversion of carbamazepine to its amorphous 
form. In the case of microfluidized solid dispersions, carbamazepine loses its 
amorphous form on prolonged exposure to medium, as indicated by the downward 
77 
slope of the solubility curve (Figures 37, & 38). However, the solid dispersions show 
only a gradual decrease in the solubility indicating a greater resistance to conversion to 
its original form. Pharmaceutical solids, as we know them, rarely exist as 100% 
crystalline or 100% amorphous phases (19). The presence of domains of one phase in 
another can act as a focal point for spontaneous phase transitions such as crystallization 
(20 - 22). The solid dispersions is likely to have reduced the number of such domains, 
thereby decreasing initiation sites for crystallization and preventing rapid conversion to 
the crystalline form as compared to the microfluidized solid dispersions. This study 
also proves that when higher proportion of polymer is used to make solid dispersions 
of carbamazepine they tend to amorphous carbamazepine with the solid dispersion. 
This fact is very useful which also suggests that at small proportion they tend to form 
small crystallites with the respective solid dispersion. 
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FIGURE 44: REPRESENTATIVE THERMOGRAM OF 
MICROFLUIDIZED SOLID DISPERSION OF CARBAMAZEPINE AND 
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( 2.9.3 Dissolution studies 
Dissolution studies aid in understanding the solubility differences between the drug, 
physical mixtures, and solid dispersions. In vitro dissolution is used to characterize the 
release behavior of different formulations. Dissolution rate data can be expressed using 
Noyes Whitney equation (23) as shown below: 
dC AD (Cs - C) 
dt h 
where dC/dt is the rate of dissolution, A is the surface area available for dissolution, D 
is the diffusion coefficient of the compound, Cs is the solubility of the drug in the 
dissolution medium, C is the concentration of drug in the medium at time t and h is the 
thickness of the diffusion boundary layer adjacent to the surface of the dissolving 
compound. 
Dissolution profiles of different ratios of drug and polymer of physical mixtures and 
solid dispersions with Solutol HS are shown in Figures 48 and 49. The dissolution 
profile of physical mixtures and solid dispersions with Vitamin E TPGS were shown in 
Figures 50 and 51. Similarly, dissolution profile of Poloxamer 188 physical mixtures 
and solid dispersions are shown in Figures 52 and 53. For dissolution studies, optimum 
ratios that were determined using optimization study were used. To find out the 
optimum ratio for the respective polymer D 10 values (dissolution rate at 10 min) was 
compared with different ratios of the respective polymer. Dissolution profile of 
physical mixtures showed that with increase in amount of polymer, dissolution rate 
increases. This trend remains same for the solid dispersions. Comparing the drug, 
physical mixtures with each respective polymer and solid dispersions with each 
90 
respective polymer, the solid dispersions gave a higher dissolution rate. Increase in the 
dissolution rate can be attributed to increased wetting of the hydrophobic drug, as there 
is increase in the dissolution rate in physical mixtures too. They also showed partial 
amorphous nature for solid dispersions, which may be another reason for the 
enhancement of dissolution rate. 
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TABLE 7: DISSOLUTION PROFILE OF CARBAMAZEPINE WITH 
DIFFERENT POLYMERS AT 80:20 (DRUG: POLYMER) 
80;20 
Timeimin_} CBZ Solutol Vit. ET Pol.188 
0 0 0 0 0 
10 1.03 10.34 11.01 28.83 
20 11.67 27.87 54.95 49.09 
30 27.27 44.6 76.62 56.11 
40 39.5 52.77 86.06 77.84 
50 44.06 58.03 89.21 83.68 
60 44.04 57.83 90.96 85.88 
75 64.06 72.88 92.29 87.69 
90 69.7 73.87 93.16 88.35 
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SUMMARY OF CONCLUSIONS 
The solid dispersions of carbamazepine with Solutol HS, Vitamin E TPGS and 
Poloxamer 188 showed enhancement in the solubility of the carbamazepine. Solid 
dispersions of carbamazepine with all the polymers increased the solubility of 
carbamazepine by different mechanisms. Physical mixtures of carbamazepine with 
different polymers showed no significant increase in solubility. From it we can 
conclude that wetting effect of surfactant is not the factor responsible for the 
enhancement of solubility. At lower content of polymer, there is no change in melting 
endotherms and crystalline patterns for solid dispersions, but higher ratios of polymer 
content showed changes in melting endotherms and crystalline patterns. This indicates 
that there may be presence of carbamazepine as very small crystallites within the 
dispersion. Lipocol C 10 which is having same HLB value as that of Vitamin E TPGS 
showed 4 times increase in solubility as compared to carbamazepine. Vitamin E TPGS 
solid dispersions showed 5 times increase in the solubility of carbamazepine. The 
varied enhancement of Lipocol C 10 and Vitamin E TPGS also suggest that they tend 
to inhibit the conversion of anhydrous carbamazepine into dihydrate form, which is the 
sole reason for lower solubility of carbamazepine when comes in contact with water. 
Microfluidization study is used to observe the effect of shear stress on the solubility of 
the solid dispersions. It showed an initial spike in solubility due to conversion of drug 
into amorphous form. But it showed rapid decline in the solubility back to equilibrium 
solubility, which is equivalent to the solubility of the carbamazepine solid dispersions. 
99 
It showed that shear stress has no effect on the solubility of solid dispersions. 
Dissolution studies also showed significant increase with different polymers at different 
ratios. The statistical model selected was adequate and unbiased. The results of 
Student-Newman-Keuls Test clearly show that if solid dispersion process and Vitamin 
E TPGS polymer is used to enhance the solubility of carbamazepine, gives significantly 
higher results as compared to other polymers. 
Physical mixtures and recrystallized mixtures showed no significant of enhancement of 
solubility. The ANOV A table showed that all the three-selected process and polymer 
variable had a significant effect on the solubility of carbamazepine. 
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APPENDIX A 
List of Publication 
The following is the journal in which the manuscript will be submitted for publication 
Manuscript I: Solubility Enhancement of Carbamazepine Using Selected Water-Soluble 
Polymers and a Solid Dispersion Technique. 
Journal: Journal of Pharmaceutical Sciences 
JOI 
( APPENDIXB 
Determination of Lambda max of Carbamazepine. 
For quantitative analysis of Carbamazepine in the solubility studies as well as in the 
dissolution studies, an ultraviolet (UV) spectrophotometer was used. A solution of 
carbamazepine in distilled water and simulated gastric fluid was scanned for ultraviolet 
absorbance between 200 and 400 nm on a Hewlett Packard 8451 A Diode Array 
Spectrophotometer. The Lambda max was found to be 284 nm. 
Construction of the Calibration curve of Carbamazepine in distilled water and 
simulated gastric fluid. 
Stock Solution: Dissolve 25.08 mg of Carbamazepine in 25 ml of methanol and 
sonicated till it gets dissolved. The concentration of solution is approximately 1 mg/ml. 
This solution is then stored at a cool and dry place. 
For calibration curve in distilled water, serial concentrations of Carbamazepine in 
distilled water using stock solutions having concentrations from 10-50 µg/ml were 
prepared. The absorbance of the prepared solutions was measured 
spectrophotometrically at Amax 284 nm. The absorbance was plotted against the 
concentration. The regression lines were calculated. 
For calibration curve in simulated gastric fluid, serial concentrations of Carbamazepine 
in simulated gastric fluid using stock solutions having concentrations from 05-30 µg/ml 
were prepared. The absorbance of the prepared solutions was measured 
spectrophotometrically at Amax 284 nm. The absorbance was plotted against the 
concentration. The regression lines were calculated. 
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TABLE 8: GROUPS FOR STUDENT-NEWMAN-KEULS TEST 
No. GROUP 
1 Carbamazepine 
2 Carbamazepine:Solutol HS (90: 10) PM 
3 Carbamazepine:Solutol HS (90: 10) SD 
4 Carbamazepine:Solutol HS (90: 10) RE 
5 Carbamazepine:Vitamin E TPGS (90:10) PM 
6 Carbamazepine:Vitamin E TPGS (90: 10) SD 
7 Carbamazepine: Vitamin E TPGS (90:10) RE 
8 Carbamazepine:Poloxamer 188 (90: 10) PM 
9 Carbamazepine:Poloxamer 188 (90: 10) SD 
10 Carbamazepine:Poloxamer 188 (90: 10) RE 
11 Carbamazepine:Lipocol C 10 (90: 10) PM 
12 Carbamazepine:Lipocol C 10 (90: 10) SD 
13 Carbamazepine:Lipocol C 10 (90: 10) RE 
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f Biopharmaceutical Classification System (BCS) of Drug classification 
The BCS is a scientific framework for classifying drug substances based on their 
aqueous solubility and intestinal permeability. When combined with the dissolution of 
the drug product, that BCS takes into a account three major factors that governs the rate 
and extent of drug absorption from solid oral dosage forms, dissolution, solubility and 
intestinal permeability. 
BCS answers - Is the dissolution rate-limiting step for absorption 
Is the gastric emptying time limiting step for absorption 
Is the permeability rate limiting step for absorption 
Is the absorption process depends on pH conditions 
It has four classes, 
Class I - High solubility + High permeability 
Class II - Low solubility + High permeability 
Class III - High solubility + Low permeability 
Class IV - Low solubility+ Low permeability 
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( Optimization Study 
To obtain the maximal dissolution rate of the drug from solid dispersions, an optimal 
weight fraction of the polymer was needed. Simonelli et al obtained similar findings 
with sulphathiazole/PVP solid dispersion. To explain this behavior, they postulated that 
the formation of a PVP outer layer (at optimal weight fraction) , which controlled the 
drug, release. If a large difference exists between the solubilities of the carrier and the 
drug, the range of weight fractions over which the dissolution is controlled by the 
carrier is very small , and occurs only at high carrier weight fractions . When Solid 
dispersions containing weight fraction over optimum were added to the surface of 
dissolution medium, gel formation was observed. Thus, the drug particles were trapped 
inside the gel and release rate was reduced. 
To determine optimum ratio for dissolution studies, dissolution rate at 10 min for each 
drug:polymer ratio was determined. For further dissolution studies ratios below 
optimum ratio were selected. 
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